Case number 2:24-cv-02689
THERAVANCE BIOPHARMA R&D IP, LLC et al v. QILU PHARMACEUTICAL CO., LTD. et al > Documents
| Date Field | Doc. No. | Description (Pages) |
|---|---|---|
| Sep 23, 2024 | 10 | STIPULATION AND ORDER CONSENT JUDGMENT AND INJUNCTION ENTERED AS OUTLINED HEREIN. SIGNED BY DISTRICT JUDGE KAI N. SCOTT ON 9/23/2024. 9/23/2024 ENTERED AND COPIES E-MAILED.(sg) (Entered: 09/23/2024) (3) |
| Sep 20, 2024 | 8 | NOTICE of Appearance by KELSEY HUGHES-BLAUM on behalf of QILU PHARMACEUTICAL CO., LTD., Qilu Pharma Inc. (HUGHES-BLAUM, KELSEY) (Entered: 09/20/2024) (2) |
| Sep 20, 2024 | 9 | STIPULATION Stipulated Consent Judgment and Injunction by MYLAN IRELAND LIMITED, Mylan Specialty L.P., THERAVANCE BIOPHARMA IRELAND LIMITED, THERAVANCE BIOPHARMA R&D IP, LLC, THERAVANCE BIOPHARMA US, INC.. (SOLLER, ERIC) (Entered: 09/20/2024) (3) |
| Sep 13, 2024 | 6 | WAIVER OF SERVICE Returned Executed by THERAVANCE BIOPHARMA R&D IP, LLC. QILU PHARMACEUTICAL CO., LTD. waiver sent on 9/11/2024, answer due 11/12/2024. (OWENS, ALEXANDER) Modified on 9/16/2024 (lisad, ). (Entered: 09/13/2024) (1) |
| Sep 13, 2024 | 7 | WAIVER OF SERVICE Returned Executed by THERAVANCE BIOPHARMA R&D IP, LLC. (OWENS, ALEXANDER) (Entered: 09/13/2024) (1) |
| Jun 20, 2024 | N/A | Attorneys are required by local rule to complete and file both a Civil Cover Sheet and a Designation Form. PLAINTIFF's counsel is directed to file COMPLETED DESIGNATION FORM in this case using the Notice (Other) docket event located in the Notices category. Signature is missing. (sbt) (Entered: 06/20/2024) (0) |
| Jun 20, 2024 | 4 | NOTICE by MYLAN IRELAND LIMITED, Mylan Specialty L.P., THERAVANCE BIOPHARMA IRELAND LIMITED, THERAVANCE BIOPHARMA R&D IP, LLC, THERAVANCE BIOPHARMA US, INC. (SOLLER, ERIC) (Entered: 06/20/2024) (1) |
| Jun 20, 2024 | 5 | Summons Issued as to QILU PHARMACEUTICAL CO., LTD., Qilu Pharma Inc.. Forwarded To: EMAILED TO PLAINTIFFS COUNSEL on 6/20/2024 (sg) (Entered: 06/20/2024) (2) |
| Jun 18, 2024 | 1 | COMPLAINT against All Defendants ( Filing fee $ 405 receipt number APAEDC-17547918.), filed by THERAVANCE BIOPHARMA R&D IP, LLC, MYLAN IRELAND LIMITED, THERAVANCE BIOPHARMA IRELAND LIMITED, THERAVANCE BIOPHARMA US, INC., Mylan Specialty L.P.. (Attachments: # 1 Exhibit A, # 2 Exhibit B, # 3 Exhibit C, # 4 Exhibit D, # 5 Exhibit E, # 6 Exhibit F, # 7 Exhibit G, # 8 Exhibit H, # 9 Civil Cover Sheet, # 10 Designation Form)(SOLLER, ERIC) (Entered: 06/18/2024) (0) |
| Jun 18, 2024 | 2 | Disclosure Statement Form pursuant to FRCP 7.1 by MYLAN IRELAND LIMITED, Mylan Specialty L.P., THERAVANCE BIOPHARMA IRELAND LIMITED, THERAVANCE BIOPHARMA R&D IP, LLC, THERAVANCE BIOPHARMA US, INC..(SOLLER, ERIC) (Entered: 06/18/2024) (2) |
| Jun 18, 2024 | 3 | Disclosure Statement Form pursuant to FRCP 7.1 by MYLAN IRELAND LIMITED, Mylan Specialty L.P., THERAVANCE BIOPHARMA IRELAND LIMITED, THERAVANCE BIOPHARMA R&D IP, LLC, THERAVANCE BIOPHARMA US, INC..(SOLLER, ERIC) (Entered: 06/18/2024) (2) |
